Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $25.1 million.

  • Relay Therapeutics' Accumulated Expenses fell 2433.77% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 2433.77%. This contributed to the annual value of $21.2 million for FY2024, which is 4261.92% up from last year.
  • Relay Therapeutics' Accumulated Expenses amounted to $25.1 million in Q3 2025, which was down 2433.77% from $23.2 million recorded in Q2 2025.
  • Relay Therapeutics' Accumulated Expenses' 5-year high stood at $33.2 million during Q3 2024, with a 5-year trough of $8.9 million in Q1 2021.
  • Over the past 5 years, Relay Therapeutics' median Accumulated Expenses value was $22.4 million (recorded in 2024), while the average stood at $22.2 million.
  • Per our database at Business Quant, Relay Therapeutics' Accumulated Expenses skyrocketed by 13536.46% in 2021 and then plummeted by 3441.4% in 2023.
  • Relay Therapeutics' Accumulated Expenses (Quarter) stood at $13.6 million in 2021, then surged by 67.46% to $22.7 million in 2022, then crashed by 34.41% to $14.9 million in 2023, then surged by 42.62% to $21.2 million in 2024, then increased by 18.35% to $25.1 million in 2025.
  • Its Accumulated Expenses was $25.1 million in Q3 2025, compared to $23.2 million in Q2 2025 and $21.0 million in Q1 2025.